NovoCure terminates LUNAR-4 phase 2 trial for metastatic NSCLC, cites real-world evidence alternative

NovoCure Ltd

Novocure GmbH terminated the LUNAR-4 phase 2 trial of Tumor Treating Fields with pembrolizumab for metastatic non-small cell lung cancer.
Decision based on availability of real-world evidence to achieve trial objectives without an interventional clinical study.
Termination is not related to any safety concerns; no impact on other Novocure studies.
Trial targeted patients previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.